CRISPR Therapeutics AG (NASDAQ:CRSP) shares are trading in the red for the eighth consecutive day on Friday. Stock down 2.73% at $77.20.
CRSP has risen 28.99% YTD, as compared to the broader S&P 500 which is up 8.12%. In the last twelve months the stock is up 61.17%.
Looking at Seeking Alpha’s Quant Ratings, this Switzerland based company has a Strong Buy rating with a score of 4.57 out of 5.
When it comes to Wall Street analysis, 11 out of 29 analysts recommend a Hold, 10 rate it as a Strong Buy, 5 rate it as a Buy, 2 rate it as Strong Sell and 1 rates it as Sell.
Seeking Alpha analysts have a Hold rating on the company with a score of 3.42 out of 5.
CRISPR and its partner Vertex Pharmaceuticals recently received regulatory approvals for Casgevy, a CRISPR/Cas9 gene-edited cell therapy for the treatment of patients who are 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia.
Speaking on the approval, SA analyst JR Research said, “The recent FDA approvals of Crispr’s gene-editing therapy have increased the actualization of its growth potential, improving investor sentiments.
With CRSP surging toward a short-term top, investors should prepare their dry powder to capitalize on a steeper pullback.”
Another analyst, Mauro Solis Vazquez Mellado said, “Investing in CRISPR Therapeutics requires risk tolerance and a long-term perspective, as the road to commercial success is complex and uncertain.”
CRSP shares rose last month as it beat its fourth quarter results on topline growth from Casgevy approval.
